| Item Type | Name |
|
Academic Article
|
Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels.
|
|
Academic Article
|
Reduction of infarct size by short-term pretreatment with atorvastatin.
|
|
Academic Article
|
The renal patient with coronary artery disease: current concepts and dilemmas.
|
|
Academic Article
|
Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.
|
|
Academic Article
|
Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: comparative effects of various pharmacologic agents.
|
|
Academic Article
|
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
|
|
Academic Article
|
Differential hemodynamic effects of oral enoximone in severe congestive heart failure.
|
|
Academic Article
|
Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin.
|
|
Academic Article
|
Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions.
|
|
Academic Article
|
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat.
|
|
Academic Article
|
Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual?
|
|
Academic Article
|
Retrograde approach to a totally occluded right coronary artery via a septal perforator artery: the tale of a long and winding wire.
|
|
Academic Article
|
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.
|
|
Academic Article
|
Treating the left main bifurcation lesion: the "three stent solution".
|
|
Academic Article
|
The acute hemodynamic response to pirbuterol at rest and exercise in patients with heart failure with observations on long-term response.
|
|
Academic Article
|
The hemodynamic effects of intravenous verapamil in patients on chronic propranolol therapy.
|
|
Academic Article
|
Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group.
|
|
Academic Article
|
Intervention in the occluded vein graft: with high risk can come great reward: review of techniques with case examples.
|
|
Academic Article
|
Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses.
|
|
Academic Article
|
Time for left main stenting in patients with LV dysfunction? Proceed with caution!
|
|
Academic Article
|
The value of recanalizing a chronic total occlusion.
|
|
Academic Article
|
Effect of chronic angiotensin converting enzyme inhibitor therapy on myocardial injury in patients undergoing percutaneous coronary interventions.
|
|
Academic Article
|
Prasugrel-induced rash.
|
|
Academic Article
|
Clinical benefits of low serum digoxin concentrations in heart failure.
|
|
Academic Article
|
Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion.
|
|
Academic Article
|
Left atrial inflow and outflow obstruction as a complication of retrograde approach for chronic total occlusion: report of a case and literature review of left atrial hematoma after percutaneous coronary intervention.
|
|
Academic Article
|
Bare-metal stent thrombosis after noncardiac surgery greater than 10 years after stent implantation.
|
|
Academic Article
|
Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme.
|
|
Academic Article
|
ST-elevation myocardial infarction as a complication of retrograde chronic total occlusion recanalization.
|
|
Academic Article
|
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
|
|
Academic Article
|
Combined intravenous pharmacotherapy in the treatment of patients with decompensated congestive heart failure.
|
|
Academic Article
|
"Drip-and-ship," "Stay-and-pray," "Freight-and-wait (and possibly inflate)" or simply opening the window wider?: Decision-making regarding time delays in the treatment of ST elevation MI.
|
|
Academic Article
|
Beyond drug therapy: nonpharmacologic care of the patient with advanced heart failure.
|
|
Academic Article
|
Letter by Uretsky regarding article, "Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the synergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) trial".
|
|
Academic Article
|
Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data.
|
|
Academic Article
|
Digoxin in the treatment of patients with chronic heart failure. Its place in therapy.
|
|
Academic Article
|
Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group.
|
|
Academic Article
|
Distal myocardial protection with intracoronary beta blocker when added to a Gp IIb/IIIa platelet receptor blocker during percutaneous coronary intervention improves clinical outcome.
|
|
Academic Article
|
Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination.
|
|
Academic Article
|
Combined therapy with dobutamine and amrinone in severe heart failure. Improved hemodynamics and increased activation of the renin-angiotensin system with combined intravenous therapy.
|
|
Concept
|
Anti-Inflammatory Agents, Non-Steroidal
|
|
Concept
|
Carbazoles
|
|
Concept
|
Adrenergic beta-Agonists
|
|
Concept
|
Adenosine
|
|
Concept
|
Biocompatible Materials
|
|
Concept
|
Carbon Dioxide
|
|
Concept
|
Digoxin
|
|
Concept
|
Benzazepines
|
|
Concept
|
Biotin
|
|
Concept
|
Cyclosporins
|
|
Concept
|
Creatinine
|
|
Concept
|
Arachidonate 5-Lipoxygenase
|
|
Concept
|
Cytochrome P-450 Enzyme System
|
|
Concept
|
Drug Evaluation
|
|
Concept
|
Contrast Media
|
|
Concept
|
Ethanolamines
|
|
Concept
|
Amidines
|
|
Concept
|
Amrinone
|
|
Concept
|
Angiotensin-Converting Enzyme Inhibitors
|
|
Concept
|
Anticoagulants
|
|
Concept
|
Antioxidants
|
|
Concept
|
Alprostadil
|
|
Concept
|
Antihypertensive Agents
|
|
Concept
|
Alloys
|
|
Concept
|
Anti-Arrhythmia Agents
|
|
Concept
|
Anti-Inflammatory Agents
|
|
Concept
|
Adrenergic beta-Antagonists
|
|
Concept
|
Anticholesteremic Agents
|
|
Concept
|
Azetidines
|
|
Concept
|
Alanine
|
|
Concept
|
Cardiotonic Agents
|
|
Concept
|
Butadienes
|
|
Concept
|
Cardiovascular Agents
|
|
Concept
|
Drug Combinations
|
|
Concept
|
Coenzymes
|
|
Concept
|
Aspirin
|
|
Concept
|
Benzylamines
|
|
Concept
|
Dopamine
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Drug Administration Routes
|
|
Concept
|
Enbucrilate
|
|
Concept
|
Calcium Channel Blockers
|
|
Concept
|
Enalapril
|
|
Concept
|
C-Reactive Protein
|
|
Concept
|
Arginine Vasopressin
|
|
Concept
|
Deferoxamine
|
|
Concept
|
Genetic Vectors
|
|
Concept
|
HLA Antigens
|
|
Concept
|
Colchicine
|
|
Concept
|
Creatine Kinase
|
|
Concept
|
Heparin
|
|
Concept
|
Isoquinolines
|
|
Concept
|
Hormones
|
|
Concept
|
Doxorubicin
|
|
Concept
|
Lactates
|
|
Concept
|
Dipyridamole
|
|
Concept
|
Mannitol
|
|
Concept
|
Enzyme Inhibitors
|
|
Concept
|
Transcription Factors
|
|
Concept
|
Diuretics
|
|
Concept
|
Ephedrine
|
|
Concept
|
Heptanoic Acids
|
|
Concept
|
Nitroglycerin
|
|
Concept
|
Drug Synergism
|
|
Concept
|
Glyburide
|
|
Concept
|
Plasminogen Activator Inhibitor 1
|
|
Concept
|
Prostaglandin-Endoperoxide Synthases
|
|
Concept
|
Serine
|
|
Concept
|
Nitroprusside
|
|
Concept
|
Leukotriene B4
|
|
Concept
|
Membrane Proteins
|
|
Concept
|
Metoprolol
|
|
Concept
|
Sulfones
|
|
Concept
|
Tissue Adhesives
|
|
Concept
|
Triiodobenzoic Acids
|
|
Concept
|
Renin
|
|
Concept
|
Calcitonin Gene-Related Peptide
|
|
Concept
|
Neurotransmitter Agents
|
|
Concept
|
Isoenzymes
|
|
Concept
|
Milrinone
|
|
Concept
|
Methoxamine
|
|
Concept
|
ATP-Binding Cassette Transporters
|
|
Concept
|
Drug Costs
|
|
Concept
|
Prednisone
|
|
Concept
|
Calcium
|
|
Concept
|
Magnesium
|
|
Concept
|
Nitroso Compounds
|
|
Concept
|
Nitric Oxide
|
|
Concept
|
Drug Monitoring
|
|
Concept
|
Tissue Plasminogen Activator
|
|
Concept
|
Chemokine CCL2
|
|
Concept
|
NG-Nitroarginine Methyl Ester
|
|
Concept
|
Morphine Derivatives
|
|
Concept
|
Phosphodiesterase Inhibitors
|
|
Concept
|
Platelet Glycoprotein GPIIb-IIIa Complex
|
|
Concept
|
Troponin T
|
|
Concept
|
Intramolecular Oxidoreductases
|
|
Concept
|
Cyclooxygenase 2
|
|
Concept
|
Interferon-alpha
|
|
Concept
|
Diatrizoate
|
|
Concept
|
Gadolinium DTPA
|
|
Concept
|
Cyclooxygenase 2 Inhibitors
|
|
Concept
|
Adrenergic beta-2 Receptor Antagonists
|
|
Concept
|
Adenosine A2 Receptor Agonists
|
|
Concept
|
Receptors, Adrenergic, beta-2
|
|
Concept
|
Platelet Aggregation Inhibitors
|
|
Concept
|
Drug-Eluting Stents
|
|
Concept
|
Prostaglandins
|
|
Concept
|
Dobutamine
|
|
Concept
|
Drug Interactions
|
|
Concept
|
Lipopolysaccharides
|
|
Concept
|
Piperazines
|
|
Concept
|
Receptors, LDL
|
|
Concept
|
Tetrazoles
|
|
Concept
|
NF-kappa B
|
|
Concept
|
Tyrphostins
|
|
Concept
|
PPAR gamma
|
|
Concept
|
Creatine Kinase, BB Form
|
|
Concept
|
Propanolamines
|
|
Concept
|
Pyrroles
|
|
Concept
|
Paclitaxel
|
|
Concept
|
Janus Kinases
|
|
Concept
|
Mitogen-Activated Protein Kinase 3
|
|
Concept
|
6-Ketoprostaglandin F1 alpha
|
|
Concept
|
Receptors, Opioid, delta
|
|
Concept
|
PTEN Phosphohydrolase
|
|
Concept
|
Smad3 Protein
|
|
Concept
|
Receptors, Purinergic P1
|
|
Concept
|
Creatine Kinase, MB Form
|
|
Concept
|
Polyethylene Terephthalates
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
|
Concept
|
Cobalt
|
|
Concept
|
Simvastatin
|
|
Concept
|
Fibrinolytic Agents
|
|
Concept
|
Iopamidol
|
|
Concept
|
Atrial Natriuretic Factor
|
|
Concept
|
Tubulin Modulators
|
|
Concept
|
Sirolimus
|
|
Concept
|
Immunologic Factors
|
|
Concept
|
Cholesterol, Dietary
|
|
Concept
|
Imidazoles
|
|
Concept
|
Iron
|
|
Concept
|
Isoxazoles
|
|
Concept
|
Hypoglycemic Agents
|
|
Concept
|
Phospholipases A
|
|
Concept
|
Metals
|
|
Concept
|
Epoprostenol
|
|
Concept
|
Norepinephrine
|
|
Concept
|
Nitriles
|
|
Concept
|
Thiophenes
|
|
Concept
|
Vasoconstrictor Agents
|
|
Concept
|
Phosphoric Monoester Hydrolases
|
|
Concept
|
Nitric Oxide Synthase Type II
|
|
Concept
|
Sodium
|
|
Concept
|
Vitamins
|
|
Concept
|
Pyridazines
|
|
Concept
|
Radioisotopes
|
|
Concept
|
Propranolol
|
|
Concept
|
Pyrazoles
|
|
Concept
|
Lisinopril
|
|
Concept
|
Thallium
|
|
Concept
|
Enoximone
|
|
Concept
|
Sulfonamides
|
|
Concept
|
Cyclooxygenase Inhibitors
|
|
Concept
|
Purines
|
|
Concept
|
Pyrrolidines
|
|
Concept
|
Verapamil
|
|
Concept
|
Prostaglandin D2
|
|
Concept
|
Lipoxins
|
|
Concept
|
Apoptosis
|
|
Concept
|
Losartan
|
|
Concept
|
Vasoactive Intestinal Peptide
|
|
Concept
|
Potassium Channels
|
|
Concept
|
Receptors, Vasopressin
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Concept
|
Cyclosporine
|
|
Concept
|
Purinergic P2Y Receptor Antagonists
|
|
Concept
|
Ubiquinone
|
|
Concept
|
Vasodilator Agents
|
|
Concept
|
Drug Eruptions
|
|
Concept
|
Drug Administration Schedule
|
|
Concept
|
Troponin I
|
|
Concept
|
Nitric Oxide Synthase
|
|
Concept
|
Enkephalin, D-Penicillamine (2,5)-
|
|
Concept
|
Phosphodiesterase 3 Inhibitors
|
|
Concept
|
Vascular Endothelial Growth Factor A
|
|
Concept
|
Oncogene Protein v-akt
|
|
Concept
|
Nitric Oxide Synthase Type III
|
|
Concept
|
Adrenergic beta-1 Receptor Antagonists
|
|
Concept
|
Thiazolidinediones
|
|
Concept
|
Phospholipases A2
|
|
Concept
|
Adrenergic beta-2 Receptor Agonists
|
|
Concept
|
Peptides
|
|
Concept
|
Theophylline
|
|
Concept
|
Receptors, Calcitonin Gene-Related Peptide
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Concept
|
Cyclooxygenase 1
|
|
Concept
|
5'-Nucleotidase
|
|
Concept
|
Cyclic AMP-Dependent Protein Kinases
|
|
Academic Article
|
Conversations in cardiology: bridging antiplatelet therapy before surgery.
|
|
Academic Article
|
Prolonged high-pressure is required for optimal stent deployment as assessed by optical coherence tomography.
|
|
Academic Article
|
Treatment of the chronic total occlusion: a call to action for the interventional community.
|
|
Academic Article
|
Fractional flow reserve in acute coronary syndrome: a word of caution.
|
|
Academic Article
|
Utility of Frequency Domain Optical Coherence Tomographic Evaluation of Angiographically Optimized Stented Lesions.
|
|
Academic Article
|
Predictors of restenosis following contemporary subintimal tracking and reentry technique: The importance of final TIMI flow grade.
|
|
Academic Article
|
Utilizing Post-Intervention Fractional Flow Reserve to Optimize Acute Results and the Relationship to Long-Term Outcomes.
|
|
Academic Article
|
The Impact of Proximal Vessel Tortuosity on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry.
|
|
Academic Article
|
Letter by Uretsky et al Regarding Article, "Prognostic Value of Fractional Flow Reserve Measured Immediately After Drug-Eluting Stent Implantation".
|
|
Academic Article
|
All stent strut malappositions are not created equal.
|
|
Academic Article
|
Retrograde recanalization of a nonchronic total occlusion lesion.
|
|
Academic Article
|
Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines?
|
|
Academic Article
|
Angio-Based Fractional Flow Reserve, Functional Pattern of Coronary Artery Disease, and Prediction of Percutaneous Coronary Intervention Result: a Proof-of-Concept Study.
|
|
Academic Article
|
In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial).
|
|
Academic Article
|
Closing the Digitalis Divide: Back to the Basics of Randomized Controlled Trials.
|
|
Academic Article
|
Do We Really Need Aspirin Loading for STEMI?
|
|
Academic Article
|
Prognostic Implications of Fractional Flow Reserve After Coronary Stenting: A Systematic Review and Meta-analysis.
|
|
Academic Article
|
Bioresorbable Vascular Scaffolds: a Dissolving Dream?
|
|
Academic Article
|
Who Should Be the Corresponding Author, What Are Their Responsibilities, and What Email Address Should They Provide?
|
|
Academic Article
|
Clinical and Vessel Characteristics Associated With Hard Outcomes After PCI and Their Combined Prognostic Implications.
|